ISRCTN15654915 https://doi.org/10.1186/ISRCTN15654915

Yorkshire Collaborative Small Cell Lung Cancer Study

Submission date 19/08/2002	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 19/08/2002	**Overall study status** Completed	
Last Edited 24/10/2019	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
TH/SMC

Study information

Scientific Title
Yorkshire Collaborative Small Cell Lung Cancer Study

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Not Specified

Health condition(s) or problem(s) studied
Lung (small cell)

Interventions
Good/moderate-prognosis patients: Patients receive chemotherapy with Ifosfamide, etoposide, mensa and vincristine (EIMV) for three courses. Patients with greater than 50% response are randomised to either:
1. Group A: No mandatory treatment, radiotherapy is optional.
2. Group B: Three further courses of EIMV chemotherapy plus optional radiotherapy.

Poor-prognosis patients: Chemotherapy is at the physicians discretion. If chemotherapy is chosen single agent etoposide or EIMV chemotherapy is recommended.

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s))
Not provided at time of registration

Completion date
01/04/1995

Eligibility

Key inclusion criteria
1. Small cell lung cancer confirmed by histological or bronchial brush or aspirate cytology.
2. Aged <75 years
3. Normal renal and hepatic function
4. No evidence of brain metastases

5. No previous specific anti-cancer treatment for current disease
6. No other malignant disease, except basal cell carcinoma and in situ carcinoma of the cervix

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Not Specified

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/1994

Date of final enrolment
01/04/1995

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Northern and Yorkshire Clinical Trials and Research Unit (UK)

Funder(s)

Funder type
Research organisation

Funder Name
Northern & Yorkshire Clinical Trials & Research Unit (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration